Q-Line Biotech IPO Final Subscription Status
Final subscription data from BSE & NSE with category-wise breakdowns
Subscription (Shares)
| Category | Offered | Applied | Times |
|---|---|---|---|
| QIB | 11,88,000 | 14,72,37,200 | 123.94 |
| NII | 8,91,600 | 13,04,65,600 | 146.33 |
| bNII (>10 Lakh) | 5,94,400 | 10,62,89,200 | 178.82 |
| sNII (2-10 Lakh) | 2,97,200 | 2,41,76,400 | 81.35 |
| Retail | 20,79,200 | 14,84,91,200 | 71.42 |
| TOTAL | 41,58,800 | 42,61,94,000 | 102.48 |
Application Breakup
| Category | Reserved | Applications | Times |
|---|---|---|---|
| NII | 743 | 49,780 | 67.00 |
| bNII (>10 Lakh) | 495 | 31,162 | 62.95 |
| sNII (2-10 Lakh) | 248 | 18,618 | 75.07 |
| Retail | 2,599 | 1,85,614 | 71.42 |
| TOTAL | 4,085 | 2,35,591 | 57.67 |
Subscription (Crores)
| Category | Offered | Demand | Times |
|---|---|---|---|
| QIB | 40.75 | 5,050.24 | 123.94 |
| NII | 30.58 | 4,474.97 | 146.33 |
| bNII (>10 Lakh) | 20.39 | 3,645.72 | 178.82 |
| sNII (2-10 Lakh) | 10.19 | 829.25 | 81.35 |
| Retail | 71.32 | 5,093.25 | 71.42 |
| TOTAL | 142.65 | 14,618.45 | 102.48 |
Day-wise Subscription
End-of-day subscription.
| Day | QIB | NII | bNII | sNII | Retail | Total |
|---|---|---|---|---|---|---|
| Day 1 21 May | 4.15x | 5.24x | 5.84x | 4.03x | 3.61x | 4.11x |
| Day 2 22 May | 5.19x | 15.96x | 18.49x | 10.90x | 9.92x | 9.86x |
| Day 3 25 May | 123.94x | 146.33x | 178.82x | 81.35x | 71.42x | 102.48x |
Estimated Allotment Chance
How Q-Line Biotech’s demand compares with recent SME IPOs
Final multiples against the 192 SME IPOs listed in the last 12 months.
| Category | Q-Line Biotech | SME median | Higher than |
|---|---|---|---|
| Overall | 102x | 3.98x | 77% of 192 |
| QIB | 124x | 14.69x | 82% of 163 |
| NII (HNI) | 146x | 5.32x | 78% of 192 |
| Retail | 71.42x | 3.5x | 76% of 192 |
Of the 44 recent SME IPOs that finished 100x or more subscribed, 91% opened above the issue price, with a median listing-day move of +42.9%. Q-Line Biotech itself listed at +31.8%.
Q-Line Biotech IPO Subscription — Detailed Analysis
Where Q-Line Biotech Subscription Finished
Q-Line Biotech IPO was subscribed 102.48 times overall by the close of bidding — a heavily oversubscribed level that signals strong investor demand. A total of 2,35,591 applications were received.
Q-Line Biotech IPO Subscription — FAQs
See also: reading the subscription table · allotment chances · allotment process
Explore More
Quick links to all IPO sections